Caribou Biosciences (NASDAQ: CRBU)
Caribou Biosciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Caribou Biosciences Company Info
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.
News & Analysis
Why Caribou Biosciences Stock Is Crashing Today
Investors didn't like the clinical-stage biotech's Q4 update for one key reason.
Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold
Buy this stock if you're daring, but avoid it for now if you aren't.
2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare
It's less scary to take on risky investments when the market is rising.
2 Exciting Biotech Stocks to Buy With Less Than $10
You can pick up these stocks for a song right now.
A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip
Wall Street price targets suggest this stock can rocket more than 400% higher.
1 Gene Editing Stock to Buy Now, and 1 to Sell
Target markets matter. So does having the cash to get to them.
3 Reasons Why Caribou Biosciences Is a Screaming Buy in July and Beyond
Early-stage biotechs almost never warrant this level of enthusiasm.
This 1 Innovation Could Make These 2 Biotechs Soar by 2030
Simplifying the cell therapy manufacturing process could be worth a lot of money.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.